greeksoup/ stocks
Stocks / India / DRREDDY / Q1 FY2025

Dr. Reddy's Laboratories Ltd. Q1 FY2025 results: revenue ₹7,696 crore, up 13.9% on the year

Dr. Reddy's Laboratories Ltd. (DRREDDY) reported consolidated revenue from operations of ₹7,696 crore for Q1 FY2025, the quarter ended 30 June 2024, up 13.9% on the same quarter a year earlier. Profit after tax was ₹1,392 crore, down 0.9% on the year, and earnings per share ₹83.61. The figures are the company's own, from the unaudited results it filed with NSE on 27 July 2024.

Revenue from operations₹7,696 croreup 13.9%
Profit after tax₹1,392 croredown 0.9%
EPS₹83.61
QuarterQ1 FY2025ended 30 June 2024

The quarter, against the one before and a year earlier

LineQ1 FY2025Q4 FY2024A year earlierChange on the year
Revenue from operations7,6967,114n/an/a
Other income187198n/an/a
Total income7,8837,311n/an/a
Cost of materials consumed1,2271,096n/an/a
Purchases of stock-in-trade1,3801,176n/an/a
Changes in inventories-426-180n/an/a
Employee benefit expense1,4141,284n/an/a
Finance costs6059n/an/a
Depreciation, depletion and amortisation381368n/an/a
Other expenses1,9711,907n/an/a
Total expenses6,0075,710n/an/a
Profit before exceptional items and tax1,8771,602n/an/a
Exceptional items00n/an/a
Profit before tax1,8771,602n/an/a
Current tax522282n/an/a
Deferred tax-3113n/an/a
Total tax490295n/an/a
Profit after tax1,3921,310n/an/a
Attributable to owners of the parentn/a0n/an/a
Other comprehensive income2-56n/an/a
Total comprehensive income1,3941,254n/an/a
EPS, basic₹83.61₹78.66n/an/a
EPS, diluted₹83.48₹78.53n/an/a

₹ crore except per share.

Quarterly results, the last 12 quarters

Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026Q1 FY2027
Sales6,9037,2377,1147,6968,0388,3818,5288,5728,8288,7537,5468,100
Expenses5,3055,6275,7106,0076,4346,6617,0516,9587,4147,4817,8277,902
Operating profit2,0082,0231,8312,1302,0762,2731,9982,1742,0101,887382860
OPM %29%28%26%28%26%27%23%25%23%22%5%11%
Other income315216198187308150522290324269475355
Interest35395960768266839194106126
Depreciation376374368381397471455476505521557537
Exceptional items000000000000
Profit before tax1,9121,8261,6021,8771,9111,8702,0001,9051,7381,541195552
Tax %23%25%18%26%30%25%21%26%23%23%-11%21%
Net profit1,4821,3811,3101,3921,3421,4041,5871,4101,3371,190221436
EPS in ₹₹89.09₹82.94₹78.66₹83.61₹15.08₹16.97₹19.12₹17.04₹16.18₹14.53₹2.65₹5.33
FilingNSENSENSENSENSENSEFilingFilingFilingFilingFilingFiling

₹ crore except per share, consolidated, as filed with the exchange. Operating profit is sales less the expenses other than interest and depreciation, OPM is that over sales, and tax % is tax over profit before tax: arithmetic on the filed lines; everything else is as filed. Quarters before December 2024 are from the exchange's earlier results feed, which carries the filed lines without the filing itself; the column links to the exchange's page for the company. EPS is as filed for each quarter. A split or a bonus issue changes the share count, so quarters before it are on the old count.

Source

Unaudited consolidated results for the quarter ended 30 June 2024, filed with NSE on 27 July 2024: the result statement. All of Dr. Reddy's Laboratories Ltd.'s results: NSE company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install